OPPORTUNITY
Mammoth is hiring a Senior Scientist I/II to contribute to R&D projects within the Editing Technologies team. The Editing Technologies team develops next-generation CRISPR tools for therapeutic genome editing applications, with scope spanning from technological ideation to translational proof-of-concept. The successful candidate will take a lead role as an individual contributor in designing novel epigenetic editing tools and developing experimental assays and workflows to evaluate their efficacy. Strength in wet lab execution and experimental design along with deep scientific understanding of epigenetics and epigenetic editing will be critical to the role. The candidate will work within a core team of epigenetic tool developers and collaborate cross-functionally with a diverse technical staff with expertise in disease biology, bioinformatics, protein engineering, high-throughput screening/automation, reagent production, and in vivo evaluation. This is a fantastic opportunity to impact human health by making CRISPR tools that cure genetic disease.
Key Responsibilities

• Contribute creatively to the design of new epigenetic editing tools through ideation and literature review
• Develop scalable assays for measuring gene and protein expression, epigenetic state, and/or cellular phenotype
• Plan, design and execute experiments for CRISPR tool evaluation
• Provide instruction to junior team members
• Document experiments in electronic laboratory notebooks and present results at internal meetings
• Disclose inventions to the IP team for patenting
• Other duties as assigned

Required Qualifications

• PhD in Molecular Biology, Cell Biology, Bioengineering or a related discipline; 3 years of relevant professional experience in industry or academia, following completion of PhD. For non-PhD candidates with a Bachelor's degree, 8 years of professional experience is required
• 2 years of hands-on experience designing and refining fusion proteins for CRISPR or other DNA binding proteins (ZNF, TALE)
• 2 years of hands-on experience designing, executing, and analyzing CRISPRa/i or epigenetic editing experiments in mammalian cells
• 3 years hands-on experience in at least two of the following areas:
• Epigenetic characterization assays including bisulfite sequencing (targeted or whole genome), EM-seq, ChIP-qPCR, and/or ChIP-seq
• b. Flow cytometry and/or fluorescence-activated cell sorting (FACS)
• c. Transcript/protein quantification assays including RT-qPCR; d/ddPCR, RNA-seq, ELISA, and/or MSD
• d. Automated methods for high-throughput molecular/cell biology workflows

Preferred Qualifications

• 2 years experience with mammalian cell line engineering
• 2 years experience with developing pooled screening approaches for high-throughput tool evaluation
• 1 years experience working with disease-specific cell models and optimizing nucleic acid delivery via lipofection, nucleofection, and/or viral transduction
• 1 years experience managing direct reports
• Working proficiency with common bioinformatics tools (Benchling, JMP, SQL, R, Python)

Benefits

• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Company-sponsored meals and snacks
• Wellness, caregiver and ergonomics benefits
• 401(k) with company matching

Base Salary Range: $ 155,000 - $182,350
The listed base salary range is for Mammoth employees in the Bay Area. Actual base salary will be determined by geographic work location, relevant professional experience, applicable skills, and internal equity. The base salary range for those working remotely outside of the San Francisco Bay Area may differ and will be determined by industry market data for the role and specific region.
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.